2023
Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review
Majem M, Basch E, Cella D, Garon E, Herbst R, Leighl N. Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review. Lung Cancer 2023, 187: 107419. PMID: 38070301, DOI: 10.1016/j.lungcan.2023.107419.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerEarly-stage diseaseHealth-related qualityClinical trialsEarly-stage non-small cell lung cancerTreatment-related adverse effectsAppropriate HRQoL instrumentNSCLC clinical trialsCell lung cancerLong-term treatmentLung cancer clinical trialsCancer clinical researchCancer clinical trialsAdjuvant treatmentAdvanced diseaseHRQOL assessmentTreatment landscapeDisease recurrenceHRQoL instrumentsLung cancerDisease progressionLife measuresHRQoLNarrative reviewHealthcare professionals
2019
1450P Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection
Tsuboi M, Herbst R, John T, Grohe C, Majem M, Goldman J, Kim S, Yu C, Miziara J, Novello S, Urban D, Akewanlop C, Öztürk A, Quang B, Kowalski D, Marmol D, Marotti M, Laus G, Wu Y. 1450P Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection. Annals Of Oncology 2019, 30: v589. DOI: 10.1093/annonc/mdz258.010.Peer-Reviewed Original ResearchNon-small cell lung cancerBristol-Myers SquibbComplete tumor resectionEGFR mutationsBoehringer IngelheimMerck SharpAdjuvant therapyComplete resectionTumor resectionStage IB-IIIA non-small cell lung cancerEGFRm non-small cell lung cancerMutation-positive non-small cell lung cancerEarly-stage non-small cell lung cancerEGFR mutation-positive non-small cell lung cancerEli LillyOral EGFR tyrosine kinase inhibitorPositive non-small cell lung cancerT790MEpidermal growth factor receptor (EGFR) mutationsEGFR T790M mutationEGFR tyrosine kinase inhibitorsGenentech/RocheNon-squamous histologySafety of osimertinibPlacebo-controlled studyTumor-Infiltrating Lymphocytes—Location for Prognostic Evaluation
Peled M, Onn A, Herbst RS. Tumor-Infiltrating Lymphocytes—Location for Prognostic Evaluation. Clinical Cancer Research 2019, 25: 1449-1451. PMID: 30567833, DOI: 10.1158/1078-0432.ccr-18-3803.Peer-Reviewed Original Research
2009
Phase II pilot study of neoadjuvant docetaxel and cisplatin followed by adjuvant erlotinib in patients with stage I-III non-small cell lung cancer (NSCLC)
Gold K, Lee J, Rice D, Tse W, Stewart D, Wistuba I, Herbst R, Lippman S, Hong W, Kim E. Phase II pilot study of neoadjuvant docetaxel and cisplatin followed by adjuvant erlotinib in patients with stage I-III non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2009, 27: 7566-7566. DOI: 10.1200/jco.2009.27.15_suppl.7566.Peer-Reviewed Original ResearchNon-small cell lung cancerStage ISurgical resectionResectable non-small cell lung cancerEarly-stage non-small cell lung cancerStage non-small cell lung cancerResponse rateECOG performance status 0Phase II pilot studyAdequate laboratory parametersCurative-intent therapyCycles of chemotherapyDefinitive surgical resectionGrade 3/4 toxicitiesPerformance status 0Radiographic response rateBenefit of chemotherapyComplete pathologic responseEncouraging response ratesCell lung cancerYr of treatmentActive regimenAdjuvant erlotinibCancer ptsEligible pts
2003
In Vitro and In Vivo Assays for the Proliferative and Vascular Permeabilization Activities of Vascular Endothelial Growth Factor (VEGF) and Its Receptor
Yano S, Herbst RS, Sone S. In Vitro and In Vivo Assays for the Proliferative and Vascular Permeabilization Activities of Vascular Endothelial Growth Factor (VEGF) and Its Receptor. Methods In Molecular Medicine 2003, 74: 391-398. PMID: 12415710, DOI: 10.1385/1-59259-323-2:391.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCapillary PermeabilityCell DivisionCells, CulturedEndothelial Growth FactorsEndothelium, VascularHumansImmunoglobulin GIn Vitro TechniquesIntercellular Signaling Peptides and ProteinsLymphokinesMaleMiceMice, Inbred C57BLMice, NudeReceptors, Vascular Endothelial Growth FactorRecombinant ProteinsTetrazolium SaltsThiazolesThymidineVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsNon-small cell lung cancerVascular endothelial growth factorLung cancerEarly-stage non-small cell lung cancerCell lung cancerNormal bronchial epitheliumEndothelial growth factorNew blood vesselsBronchial dysplasiaPoor prognosisPrimary tumorLung carcinogenesisMicrovascular densityBronchial epitheliumSolid tumorsBlood vesselsGrowth factorTumorsMetabolic demandsVivo assaysCancerEarly stagesCarcinomaPrognosisHyperplasia